Zobrazeno 1 - 10
of 57
pro vyhledávání: '"D K Armstrong"'
Autor:
D Lavoie, N Pinet, S Zhang, J Reyes, C Jiang, O H Ardakani, M M Savard, R S Dhillon, Z Chen, J R Dietrich, K Hu, J A Craven, B Roberts, M J Duchesne, V I Brake, G Huot-Vézina, J M Galloway, A D McCracken, E Asselin, V Decker, M Beauchemin, M P B Nicolas, D K Armstrong, K E Hahn
As part of its Geo-mapping for Energy and Minerals program, the Geological Survey of Canada included the Hudson Bay Basin in its research portfolio with the goal of generating a modern understanding of its geological framework and a precise knowledge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e721c256bb7904c38780947f95bd7f1
https://doi.org/10.4095/326090
https://doi.org/10.4095/326090
Autor:
Franco M. Muggia, Roger B. Lee, Peter G. Rose, D. K. Armstrong, David G. Mutch, Angeles Alvarez Secord, Linda Van Le, Saketh R. Guntupalli, James J. Java, Larry J. Copeland, Chad A. Hamilton, Maurie Markman, Robert A. Burger, Michael Friedlander, David Bender, Ritu Salani, Krishnansu S. Tewari, Michael A. Bookman, Robert M. Wenham, Michael Method, Melissa A. Geller
Publikováno v:
Obstetrics & Gynecology. 133:245-254
Objective To analyze clinical prognostic factors for survival after recurrence of high-grade, advanced-stage ovarian-peritoneal-tubal carcinoma and to develop a nomogram to predict individual survival after recurrence. Methods We retrospectively anal
Autor:
T. Cameron, Nicoletta Colombo, Robert L. Coleman, Giovanni Scambia, Elizabeth M. Swisher, Ana Oaknin, Jeffrey C. Goh, J García-Donas, David M. O'Malley, Johanne I Weberpals, M. Amenedo Gancedo, Amit M. Oza, Peter C.C. Fong, Carol Aghajanian, Andrew Dean, Andrew R Clamp, Jonathan A. Ledermann, Alexandra Leary, Susana Banerjee, Domenica Lorusso, Sandra Goble, D. K. Armstrong, Robert W. Holloway, Lara Maloney
Publikováno v:
Oral Communication 3 – Ovarian Cancer.
Introduction/Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-free survival (PFS) vs placebo in all patient populations, regardless of biomarker status (Coleman et al. Lancet. 2017;390:1949–61). This subgroup
Autor:
M. Amenedo Gancedo, Nicoletta Colombo, Andrew R Clamp, Robert L. Coleman, Elizabeth M. Swisher, Susana Banerjee, Domenica Lorusso, Robert W. Holloway, Peter C.C. Fong, T. Cameron, Carol Aghajanian, Johanne I Weberpals, Jeffrey C. Goh, Josh Bedel, Jonathan A. Ledermann, David M. O'Malley, Amit M. Oza, Juliette Meunier, Ana Oaknin, J García-Donas, Giovanni Scambia, Andrew Dean, Sandra Goble, Alexandra Leary, D. K. Armstrong, Lara Maloney
Publikováno v:
Oral Communication 3 – Ovarian Cancer.
Introduction/Background Maintenance therapy for recurrent ovarian cancer is intended to extend progression-free survival (PFS) without compromising patient quality of life; therefore, the clinical benefits of prolonged PFS should be evaluated in the
Autor:
Ursula A. Matulonis, D. K. Armstrong, Michael J. Birrer, Cesar M. Castro, Michael V. Seiden, Don S. Dizon, Carolyn N. Krasner, Mark A. Morgan, Maria Roche, Richard T. Penson, J.K. Wolfe, Hang Lee, Jeffrey G. Supko, Charles W. Drescher
Publikováno v:
Gynecologic oncology. 153(2)
Background Intraperitoneal (IP) chemotherapy can improve outcomes for women with optimally cytoreduced epithelial ovarian cancer but toxicities are a concern. We conducted 2 phase 2 trials of an IV/IP regimen using carboplatin and paclitaxel without
Autor:
Roisin E. O'Cearbhaill, Katherine M. Bell-McGuinn, A. Miller, Sarah W. Gordon, C.R. Washington, Cara Mathews, David M. O'Malley, Linda R. Duska, Alice P. Chen, Heidi J. Gray, Saketh R. Guntupalli, Russell J. Schilder, D. K. Armstrong, Andrea R. Hagemann, W.E. Brady, Joan L. Walker, Carol Aghajanian, Kathleen N. Moore
Publikováno v:
Gynecologic Oncology. 159:16
Autor:
Andrea R. Hagemann, Katherine M. Bell-McGuinn, Heidi J. Gray, Alice P. Chen, Sarah W. Gordon, Russell J. Schilder, C.R. Washington, Joan L. Walker, Carol Aghajanian, Kathleen N. Moore, Linda R. Duska, D. K. Armstrong, A. Miller, Saketh R. Guntupalli, W.E. Brady, David M. O'Malley, Roisin E. O'Cearbhaill, Cara Mathews
Publikováno v:
Gynecologic Oncology. 159:88
Autor:
David G. Mutch, J I Weberpals, Roberto Sabbatini, D K Armstrong, Susana Banerjee, Domenica Lorusso, Giovanni Scambia, Gottfried E. Konecny, Jonathan A. Ledermann, A Leary, T Neunhöffer, Hani Gabra, J C Goh, G Kichenadasse, R W Holloway, Iris L. Romero, Jesus Garcia-Donas, Martin Buck, Michael Friedlander, Nicoletta Colombo, Robert L. Coleman, Deborah K. Armstrong, Amnon Amit, E M Guerra, Stephen Welch, Salomon M. Stemmer, T Vanderkwaak, C Hänle, Ignace Vergote, Alain Lortholary, Laurence Gladieff, David M. O'Malley, J Garcia-Donas, A Clamp, James Sun, Andrew R Clamp, Mitch Raponi, Laurie Elit, Claudio Zamagni, R T Morris, A Casado Herraez, Y Drew, Benoit You, Thomas Harding, M Vulfovich, L Ma, B M Slomovitz, S Kovel, A Dean, C Aghajanian, Prafull Ghatage, A O'Donnell, L-m Chen, Diane Provencher, G Scambia, D M O'Malley, A El-Balat, Jeffrey C. Goh, M Leviov, Florence Joly, Ronnie Shapira-Frommer, Olivier Tredan, Marie Plante, Stefano Tamberi, Amit M. Oza, Kevin K. Lin, G E Konecny, E M Swisher, A Oaknin, I A McNeish, Johanne I Weberpals, Clare L. Scott, M Amenedo Gancedo, Paul R. Harnett, Mark A. Morgan, A Floquet, Jean-Pierre Lotz, Terri Cameron, Ana Oaknin, Elizabeth M. Swisher, Michael J. Birrer, Setsuko K. Chambers, Peter C.C. Fong, Andrew Dean, Carol Aghajanian, Sandro Pignata, Melanie E Powell, Alessandra Bologna, Caroline Grace, Christine Parkinson, C L Scott, Jeff Isaacson, J. Medioni, Heidi Giordano, Tamar Safra, H Denys, I Palacio, P C Fong, Margarita Amenedo Gancedo, Robert W Holloway, P Krabisch, N Colombo, Mary K. Buss, Alexandra Leary, Pauline Wimberger, A Sanchez, Luc Dirix, Sandra Goble, M Pölcher, Lara Maloney, Anne Floquet, D Jackson, Iain A. McNeish
Publikováno v:
Lancet (London, England), vol 390, iss 10106
Background: \ud \ud Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0275ed6179ab07f49e1cdef255c13c2
http://hdl.handle.net/10281/171093
http://hdl.handle.net/10281/171093
Autor:
Kathleen M. Darcy, D. K. Armstrong, Angeles Alvarez Secord, Shalini L Kulasingam, Laura J. Havrilesky
Publikováno v:
Journal of Clinical Oncology. 26:4144-4150
Purpose To determine the cost effectiveness of intraperitoneal versus intravenous regimens for adjuvant treatment of optimally resected stage III ovarian cancer. Patients and Methods A decision model was developed to compare the cost effectiveness at
Autor:
T Woo Kim, P-J. Chen, T-C Wu, Sara I. Pai, Liangmei He, C-T Lin, J.W. Kim, David A.K. Boyd, D K Armstrong, C-F Hung, Jeremy Juang
Publikováno v:
Gene Therapy. 11:1011-1018
Intradermal vaccination via gene gun efficiently delivers DNA vaccines into dendritic cells (DCs) of the skin, resulting in the activation and priming of antigen-specific T cells in vivo. In the context of DNA vaccines, we previously used the gene gu